Trial Profile

Pilot Study of the Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011) Following Doxorubicin (Adriamycin) and Cytoxan as Neo-adjuvant Therapy in Glycoprotein NMB-expressing High Risk Triple Negative Breast Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase 0

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Glembatumumab vedotin (Primary)
Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Adverse reactions
Acronyms Breast50

30 May 2018 Planned End Date changed from 31 Mar 2023 to 31 May 2018.
30 May 2018 Planned primary completion date changed from 31 Mar 2021 to 2 May 2018.
30 May 2018 Planned initiation date changed from 31 Mar 2018 to 1 May 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com